News coverage about Johnson & Johnson (NYSE:JNJ) has been trending somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Johnson & Johnson earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.2092275870474 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news articles that may have effected Accern Sentiment’s rankings:
Shares of Johnson & Johnson (NYSE:JNJ) opened at $145.76 on Friday. The stock has a market cap of $391,590.00, a PE ratio of 25.31, a P/E/G ratio of 2.73 and a beta of 0.80. Johnson & Johnson has a fifty-two week low of $110.76 and a fifty-two week high of $146.42. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.80 by $0.10. The firm had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. Johnson & Johnson’s revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm earned $1.68 EPS. equities analysts predict that Johnson & Johnson will post 7.28 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th will be paid a dividend of $0.84 per share. The ex-dividend date is Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a yield of 2.31%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.
JNJ has been the subject of a number of recent research reports. Vetr lowered shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 price target for the company. in a research report on Monday, September 18th. Goldman Sachs Group lowered shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and lifted their target price for the company from $125.00 to $130.00 in a report on Wednesday, September 20th. Citigroup started coverage on shares of Johnson & Johnson in a report on Monday, September 25th. They set a “neutral” rating and a $140.00 target price for the company. Zacks Investment Research cut shares of Johnson & Johnson from a “hold” rating to a “sell” rating in a research note on Wednesday, September 27th. Finally, UBS Group reissued a “buy” rating and issued a $148.00 price target on shares of Johnson & Johnson in a research note on Saturday, September 30th. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $145.94.
ILLEGAL ACTIVITY NOTICE: “Johnson & Johnson (NYSE:JNJ) Getting Somewhat Favorable Media Coverage, Accern Reports” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/13/johnson-johnson-jnj-earns-news-impact-rating-of-0-14.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.